Asset
ELIRONRASIB
REVOLUTION MEDICINES INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05462717 | phase1 | active_not_recruiting | 2022-09-19 | 2027-03-31 | Revolution Medicines, Inc. | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors |
| NCT06128551 | phase1_2 | recruiting | 2023-11-14 | 2028-12-01 | Revolution Medicines, Inc. | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors |
| NCT07397338 | phase1_2 | recruiting | 2026-01-30 | 2029-05-01 | Revolution Medicines, Inc. | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors |
| NCT06162221 | phase1_2 | recruiting | 2024-01-18 | 2027-06-01 | Revolution Medicines, Inc. | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC |
FDA applications (0)
This company has no applications containing this asset.